Type 2 Diabetes Under ICH E6(R3)
The "Type 2 Diabetes Cardiometabolic Operations Playbook"
What this playbook operationalizes
Type 2 diabetes / cardiometabolic trials must be designed and run as chronic-care trial systems, not as isolated efficacy exercises. Endpoint interpretability depends not only on whether scheduled assessments occur, but on whether the Sponsor prospectively governs the care-pathway variables most likely to alter treatment effect interpretation.
Under ICH E6(R3), the Sponsor is expected to identify Critical-to-Quality (CtQ) factors early and implement fit-for-purpose controls before the first participant is screened. In Type 2 diabetes / cardiometabolic development, this requirement is operationally important because trial outcomes are shaped by two interacting streams:
Who this is for
- Clinical Operations leaders planning Phase II or Phase III T2D / cardiometabolic programs
- Clinical Development leaders accountable for endpoint interpretability
- Quality / GCP / inspection-readiness stakeholders
- Teams considering hybrid, device-enabled, or globally distributed trial models
What is inside the pack
- A practical 3-Pillar QbD Defense for T2D / cardiometabolic trials
- A red/yellow protocol audit scorecard
- The no silent thresholds rule: if it is not in the final protocol or plans, mark it needs confirmation
- A worked Objective → Trigger → Action → Evidence control-loop example
- A glycemic endpoint reconciliation example
- A SAP Log / endpoint defensibility example
- A starter list of Draft 0.5 issues that create later rework and inspection vulnerability
Planning a Type 2 Diabetes trial?
Book the 30-minute Inspection-Readiness Stress Test
Hybrid / Device-Enabled Execution: Provable Data by Design
- explicit source-of-truth rules for HbA1c and key glycemic endpoints
- supportive digital/device data remain supportive unless explicitly endpoint-defining
- chain-of-custody map: participant/device/app → vendor → Sponsor/Accelsiors → EDC → analysis
- predefined reconciliation workflow for:
- non-sync
- latency
- provenance breach
- source ambiguity
- vendor oversight evidence:
- qualification
- transfer validation
- audit trail extractability
- KPI pack
- incident/CAPA governance
Endpoint Defensibility: Operational Evidence That Supports the SAP
- protocol ↔ SAP ↔ DMP/CMP alignment before screening
- explicit handling of:
- discontinuation
- rescue therapy
- treatment intensification
- insulin initiation / major change
- missed key HbA1c visits
- temporary DCT gaps
- controlled SAP Log governance
- source-of-truth rules:
- HbA1c primary
- supportive digital data remain supportive unless explicitly endpoint-defining
- analysis-impacting events must leave an evidence trail, not just an email trail
